Angemeldet als:
filler@godaddy.com
PK/PD Modelling Model-informed Drug Development Precision
PK Analysis : An essential step in the drug development Process
Pharmacokinetics (PK) describes what the human body does to a given molecule, from the time of administration to absorption, distribution, metabolism and excretion from the body. By assessing of a molecule in different samples. We can understand a molecule's interaction with the body, as well as the intensity and duration of efficacy.
Pharmacodynamics (PD) studies the physiological and molecular effects of a molecule on the body and involves receptor binding, post-receptor effects and chemical interactions.
Together PK/PD data undergoing precision mathematical and statistical premium techniques explain the dose-response relationship of a molecule and are integral in designing the dose, route and schedule of administration to maximise effectiveness while reducing adverse effects.
Understanding the pharmacokinetic and pharmacodynamic behaviour of a given molecule is Ana essential element of understanding its effectiveness and safety, as well as identifying the proper dosage and distribution.
Helping clients determine dosage levels for drug efficacy and toxicity
We offer Pharmacokinetic / Pharmacodynamic modelling using unbiased mathematical and statistical techniques as recommended by the National Institutes of Health (NIH) and International Committee of Harmonisation (ICH) to help our clients choose a precise model that provides insights into the pharmacokinetic characteristics of a given molecule and hence aid the interpretation of dose-response and dose escalation during preclinical phases and further phases when necessary.
Our expertise lies in providing robust and unbiased data
Pharmacokinetic and pharmacodynamic characteristics evaluation.
PK/PD efficacy correlations.
PK/PD Modelling.
Predicting safe dose.
predicting toxicity dose.
The value of our services to our clients, the community, environment and nature
By implying our reliable quantified PK/PD Models our clients can save up to 50% of the trial time by reducing the possibility of errors.
Providing significant evidence based information in clinical trials.
Minimising unexpected hazards while holding the clinical trial.
support reducing the number of animals used in a trial.
ensure the reduction of hazardous wastes of the molecule to be tested in the trial.
enhancing the chances to get an approval for conducting the trial.